The impact of proteases on wound healing has been widely accepted for some time. This Made Easy discusses how combining technologies and materials to increase product functionality will ensure better outcomes for patients, as our understanding of chronic wound pathophysiology improves. For example, utilising a strategy for excess protease activity that deals with just MMPs addresses only a small part of the problem. In instances where other proteases are in excess, other modes of action are also needed.
Supported by KCI – An Acelity Company
